199851-89-3Relevant academic research and scientific papers
C6-structural optimizations of 2-aryl-1H-pyrazole-S-DABOs: From anti-HIV to anti-DENV activity
Rui, Ruo-Mei,Tang, Cheng-Run,Zhang, Chun-Tao,Pan, Wen-Kai,Gan, Kai,Luo, Rong-Hua,Wei, Zi-Qian,Jing, Fan-Shun,Huang, Si-Ming,Yang, Liu-Meng,Li, Yi-Ming,Wang, Yue-Ping,Xiao, Wei-Lie,Zhang, Hong-Bing,Zheng, Yong-Tang,He, Yan-Ping
, (2021/11/30)
Both HIV and DENV are serious threats to human life, health and social economy today. So far, no vaccine for either HIV or DENV has been developed successfully. The research on anti-HIV or DENV drugs is still of great significance. In this study we developed a series of novel 2-Aryl-1H-pyrazole-S-DABOs with C6-strucutral optimizations as potent NNRTIs, among which, 8 compounds had low cytotoxicity and EC50 values in the range of 0.0508 ～ 0.0966 μM, and their selectivity index was SI > 1415 ～ 3940. In particular, two compounds 4a and 4b were identified to have good inhibitory effects on DENV of four serotypes. The EC50 of compound 4a and 4b against DENV-II (13.2 μM and 9.23 μM, respectively) were better than that of the positive control ribavirin (EC50 = 40.78 μM). In addition, the effect of C-6 substituents on the anti-HIV or anti-DENV activity of these compounds was also discussed.
Synthesis and Antiviral Evaluation of 1-[(2-Phenoxyethyl)oxymethyl] and 6-(3,5-Dimethoxybenzyl) Analogues of HIV Drugs Emivirine and TNK-651
El-Brollosy,Loddo
, p. 181 - 188 (2016/05/02)
Novel emivirine analogues 6a, b were synthesized by reacting chloromethyl ethyl ether with 5-ethyl/isopropyl-6-(3,5-dimethoxybenzyl)uracils 5e, f. On the other hand, A series of new TNK-651 analogues 10a-f substituted at N-1 with phenoxyethoxymethyl moiety was prepared on treatment of the corresponding uracils 5a-f with bis(phenoxyethoxy)methane (9). The newly synthesized non-nucleosides were tested for antiviral activity against wild type HIV-1 IIIB as well as the resistant strains N119 (Y181C), A17 (K103N+Y181C), and the triple mutant EFVR (K103R+V179D+P225H) in MT-4 cells. Most of the tested compounds showed good activities. Among them 6-(3,5-dimethylbenzyl)-5-ethyl-1-[(2-phenoxyethyl)oxymethyl]uracil (10c) and 6-(3,5-dimethylbenzyl)-5-isopropyl-1-[(2-phenoxyethyl)oxymethyl]uracil (10d) that showed inhibitory potency higher than emivirine against both wild type HIV-1 and the tested mutant strains, as well as higher activity than efavirenz against EFVR.
New efficient and flexible synthetic route to Emivirine and its analogs
Li, Li,Ma, Liying,Wang, Xiaowei,Liu, Junyi
, p. 164 - 168 (2013/04/24)
A revised synthetic route to Emivirine (MKC-442) via properly substituted β-keto ester converted from Meldrum's Acid was developed. This method could be applied to the synthesis of a variety of MKC-442 analogues and open the way for their systematic biological evaluation.
Synthesis of novel uracil non-nucleoside derivatives as potential reverse transcriptase inhibitors of HIV-1
El-Brollosy, Nasser R.,Al-Deeb, Omar A.,El-Emam, Ali A.,Pedersen, Erik B.,La Colla, Paolo,Collu, Gabriella,Sanna, Giuseppina,Loddo, Roberta
experimental part, p. 663 - 670 (2010/06/12)
Novel emivirine and TNK-651 analogues 5a-d were synthesized by reaction of chloromethyl ethyl ether and / or benzyl chloromethyl ether, respectively, with uracils having 5-ethyl and 6-(4-methylbenzyl) or 6-(3,4-dimethoxybenzyl) substituents. A series of new uracil non-nucleosides substituted at N-1 with cyclopropylmethyloxymethyl 9a-d, 2-phenylethyloxymethyl 9e-h, and 3-phenylprop-1-yloxymethyl 9i-l were prepared on treatment of the corresponding uracils with the appropriate acetals 8a-c. Some of the tested compounds showed good activity against HIV-1 wild type. Among them, 1-cyclopropylmethyloxymethyl- 5-ethyl-6-(3,5-dimethylbenzyl)uracil 9c and 5-ethyl-6-(3,5-dimethylbenzyl)-1-(2- phenylethyloxymethyl)uracil 9g showed inhibitory potency equally to emivirine against HIV-1 wild type. Furthermore, compounds 9c and 9g showed marginal better activity against NNRTI resistant mutants than emivirine.
Synthesis and anti-HIV-1 activity of S-dihydro(alkyloxy)benzyloxypyrimidine derivatives
Rao, Zhi-Kun,Long, Jing,Li, Cong,Zhang, Sui-Shuan,He, Mei,Ou, Ling-Cheng,Zheng, Yong-Tang,He, Yan-Ping
scheme or table, p. 967 - 974 (2009/10/16)
Several 2-heteroaryl-, 2-heteroarylcarbonylmethyl-, 2-arylcarbonylmethyl, and 2-arylethyl derivatives of S-dihydro(alkyloxy)benzyloxypyrimidines have been synthesized and the anti-HIV activities of these compounds were tested in C8166 cell and against RT
Does the 2-methylthiomethyl substituent really confer high anti-HIV-1 activity to S-DABOs?
Sbardella, Gianluca,Mai, Antonello,Artico, Marino,Massa, Silvio,Marceddu, Tiziana,Vargiu, Laura,Marongiu, Maria Elena,La Colla, Paolo
, p. 30 - 39 (2007/10/03)
S-DABO derivatives containing the methylthiomethyl (MTM) group have been synthesized and tested for anti-HIV-1 activity in cell-based assay (MTT and p24 assays) and for their capability to target the HIV-1 reverse transcriptase in enzyme assays. Data of experiments lead to the conclusion that the introduction of a 2-MTM-thio side chain is not sufficient per se to significantly increase S-DABO's potency. Nevertheless, potent MTM-S-DABOs can be obtained by introducing a 2,6-difluorophenylmethyl moiety as a C-6 substituent.
5-alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series
Vig, Rakesh,Mao, Chen,Venkatachalam,Tuel-Ahlgren, Lisa,Sudbeck, Elise A.,Uckun, Fatih M.
, p. 1461 - 1466 (2007/10/03)
Novel dihydroalkoxybenzyloxopyrimidine (S-DABO) derivatives targeting the non-nucleoside inhibitor (NNI) binding site of human immunodeficiency virus (IV) reverse transcriptase (RT) have been synthesized using a novel computer model for the NNI binding pocket and tested for their RT inhibitory activity in cell-free assays using purified recombinant HIV RT as well as for their anti-HIV activity in HTLVIIIB-infected peripheral blood mononuclear cells. Our computational approach allowed the identification of several ligand derivatization sites for the generation of more potent S-DABO derivatives. Our lead S-DABO derivative, 5-isopropyl-2- [(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-one (compound 3), elicited potent anti-HIV activity with an IC50 value of less than 1nM for inhibition of HIV replication without any evidence of cytotoxicity and an unprecedented selectivity index of > 100,000.
Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase
Sudbeck, Elise A.,Mao, Chen,Vig, Rakesh,Venkatachalam,Tuel-Ahlgren, Lisa,Uckun, Fatih M.
, p. 3225 - 3233 (2007/10/03)
Two highly potent dihydroalkoxybenzyloxopyrimidine (DABO) derivatives targeting the nonnucleoside inhibitor (NNI) binding site of human immunodeficiency virus (HIV) reverse transcriptase (RT) have been designed based on the structure of the NNI binding pocket and tested for anti-HIV activity. Our lead DABO derivative, 5-isopropyl-2-[(methylthiomethyl)thio]- 6-(benzyl)-pyrimidin-4-(1H)-one, elicited potent inhibitory activity against purified recombinant HIV RT and abrogated HIV replication in peripheral blood mononuclear cells at nanomolar concentrations (50% inhibitory concentration, 1 nM) but showed no detectable cytotoxicity at concentrations as high as 100 μM.
Synthesis of an AZT-HEPT hybrid and homologous AzddU derivatives
Larsen, Erik,Danel, Krzysztof,Vaaben, Gitte B.,El-Emam, Ali A.,Pedersen, Erik B.,Nielsen, Claus
, p. 417 - 421 (2007/10/03)
3′-Azido-2′,3′-dideoxyuridines 6 and their corresponding α anomers 5 were syrthesizes by condensation of silylated 6-alkyl and 5,6-dialkyl substituted uracils 2 with methyl 3-azido-5-O-tert-butyldiphenylsilyl-2,3-dideoxy-α,β-D-erythro- pentofuranoside (4). Compounds 5 and 6 were treated with tetrabutylammonium fluoride to obtain the deprotected nucleosides 7 and 8, respectively. Acta Chemica Scandinavica 1996.
Easy synthesis of 5,6-disubstituted acyclouridine derivatives
Danel,Larsen,Pedersen
, p. 934 - 936 (2007/10/02)
Ethyl 2-ethyl-3-oxo-4-phenylbutyrate is synthesized in a high yield from the corresponding benzyl cyanide and ethyl 2-bromobutyrate or by reaction of the potassium salt of ethyl 2-ethylmalonate with phenylacetyl chloride. Condensation of the 3-oxo ester w
